Navigation Links
Extra Drug Improves Rectal Cancer Treatment
Date:4/15/2008

And contraceptive drug helps kill cervical cancer cells missed by chemotherapy

TUESDAY, April 15 (HealthDay News) -- Adding the cancer drug Avastin to radiation and chemotherapy improves results for patients with rectal cancer.

And adding the contraceptive drug mifepristone (RU-486, the so-called abortion pill) to chemotherapy kills ovarian cancer cells that escaped cisplatin treatment.

Those are the conclusions of two reports on new trends in cancer drugs presented Tuesday at the American Association for Cancer Research annual meeting, in San Diego.

In the first study, researchers found that adding Avastin to chemotherapy and radiation improved three-year, disease-free survival by 91 percent among patients with rectal cancer.

"Avastin is an antibody against a potent angiogenic molecule known as vascular endothelial growth factor (VEGF) and has been approved to treat several types of cancers," Rakesh K. Jain, director of the Edwin L. Steele Laboratory for Tumor Biology at Massachusetts General Hospital, said during a teleconference. In essence, VEGF promotes the growth of blood vessels in cancer tumors, he said.

According to the U.S. National Cancer Institute, there are more than 40,000 new cases of rectal cancer diagnosed each year in the United States.

The goal of Jain's team's research was to find ways to make standard chemotherapy more effective. For the study, 25 patients with rectal cancer were treated with Avastin, along with chemotherapy and external beam radiation and surgery. The addition of Avastin increased the density of blood vessels in the tumor and repaired tumor vessels damaged by chemotherapy or radiation, he said.

"Avastin leads to vessel normalization, it repairs vessels," Jain said. "By repairing the vessels, it makes the tumor better-nourished so the drugs can get there and work better," he said. "That's a very counterintuitive finding."

Avastin alone, or in combination with other treatments, increased levels of the factors VEGF, PlGF and SDF1 alpha, the researchers reported. Patients with higher levels of VEGF and PlGF after Avastin responded better to chemotherapy and radiation, Jain said.

The increase in SDF1 alpha suggests that this factor could be a new drug target to extend the life of patients after other therapies have failed, Jain said. "This is a new drug candidate," he said.

Among the patients receiving Avastin, local control of their disease reached 100 percent, Jain said. "Three-year, progression-free survival was 91 percent," he said.

Jain cautioned, however, that these results were very preliminary and needed to be confirmed.

In the second study, researchers found that using mifepristone along with the chemotherapy drug cisplatin might improve success in treating ovarian cancer.

"Mifepristone, which was initially created for contraceptive purposes, has a therapeutic effect against ovarian cancers that remained after standard cisplatin therapy," lead researcher Dr. Carlos M. Telleria, an assistant professor of medicine at the University of South Dakota Sanford School of Medicine, said during Tuesday's teleconference.

One of the main problems in treating ovarian cancer is that the usual treatment with the chemotherapy drug cisplatin doesn't kill all the cancer cells. This allows the cells to reform into colonies and the cancer to continue to grow.

"We show for the first time that mifepristone is effective in preventing the re-growth of ovarian cancer cells that survive standard cisplatin chemotherapy," Telleria said.

There are more than 20,000 women diagnosed with ovarian cancer every year in the United States, and more than 15,000 women die from the disease annually, Telleria noted.

In the study, the researchers exposed ovarian cancer cells to cisplatin. Although cisplatin killed the majority of the cells, there were cells that escaped and regrouped as cancer. This happened all three times the cells were treated with cisplatin over 36 days.

However, when cells were treated with cisplatin and then exposed to mifepristone, none of the cancer cells survived, the researchers found.

"This study suggests that mifepristone has the potential to improve the success of the standard platinum drugs in the treatment of ovarian cancer," Telleria said.

More information

For more on cancer, visit the American Cancer Society.



SOURCES: April 15, 2008, teleconference with Rakesh K. Jain, Ph.D., director, Edwin L. Steele Laboratory for Tumor Biology, Massachusetts General Hospital, Boston; Carlos M. Telleria, M.D., assistant professor of medicine, University of South Dakota Sanford School of Medicine, Vermillion; American Association for Cancer Research annual meeting, San Diego


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Green Tea, Mushroom Extract Combo Slows Sarcomas
2. Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma
3. Crannose(TM) Extra Strength Womens Health Formula Targets Urinary Tract Infections
4. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
5. Apple pectin, apple juice extracts shown to have anticarcinogenic effects on colon
6. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
7. Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology
8. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
9. GetWellNetwork Partners with DAISY Foundation to Recognize Extraordinary Nurses
10. Broccoli Sprout Extract Hinders Bladder Cancer Development
11. Do todays young people really think they are so extraordinary?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: